Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

 


Get this Report



PayPal Verified Vendor

Rating

4.8 Star Rating for report Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 463
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resistant prostate cancer is characterized by rising prostate specific antigen (PSA) with a low testosterone and is associated with poor prognosis. mHRPC arises when prostate cancer becomes non-responsive to hormone therapy and spreads to neighboring tissues or to other parts of the body such as the bones. Some of the most important predisposing factors for mHRPC include increasing age, environmental stress and genetic factors. Symptoms of mHRPC may include lethargy, paraplegia, bone pain, lower back or pelvic pain and weight loss. It may be controlled by hormonal therapy, radiation therapy or chemotherapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.

Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resistant prostate cancer is characterized by rising prostate specific antigen (PSA) with a low testosterone and is associated with poor prognosis. mHRPC arises when prostate cancer becomes non-responsive to hormone therapy and spreads to neighboring tissues or to other parts of the body such as the bones. Some of the most important predisposing factors for mHRPC include increasing age, environmental stress and genetic factors. Symptoms of mHRPC may include lethargy, paraplegia, bone pain, lower back or pelvic pain and weight loss. It may be controlled by hormonal therapy, radiation therapy or chemotherapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-30 

Report: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 7
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 8
Therapeutics Development 9
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 11
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 16
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 19
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 25
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 26
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 87
Drug Profiles 101
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 433
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 438
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 441
Appendix 452
 

List of Tables

List of Tables
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 19
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Development, H2 2016 28
Products under Development by Companies, H2 2016 29
Products under Development by Companies, H2 2016 (Contd..1) 30
Products under Development by Companies, H2 2016 (Contd..2) 31
Products under Development by Companies, H2 2016 (Contd..3) 32
Products under Development by Companies, H2 2016 (Contd..4) 33
Products under Development by Companies, H2 2016 (Contd..5) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2016 36
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc, H2 2016 37
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 38
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis Inc, H2 2016 39
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx Inc, H2 2016 40
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc, H2 2016 41
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 42
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 43
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule Inc, H2 2016 44
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 45
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arvinas Inc, H2 2016 46
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016 47
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016 48
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 49
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 50
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 51
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016 52
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 53
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 54
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corp, H2 2016 55
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016 56
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016 57
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 58
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 59
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Curevac AG, H2 2016 60
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016 61
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016 62
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte Inc, H2 2016 63
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016 64
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 65
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016 66
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016 67
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 68
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx Inc, H2 2016 69
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 70
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 71
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2016 72
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MedImmune LLC, H2 2016 73
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation Inc, H2 2016 74
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MEI Pharma Inc, H2 2016 75
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 76
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corp, H2 2016 77
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2016 78
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016 79
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 80
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 81
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc, H2 2016 82
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 83
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Selexel, H2 2016 84
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio as, H2 2016 85
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc, H2 2016 86
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 87
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 88
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro Inc, H2 2016 89
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 90
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd, H2 2016 91
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals Inc, H2 2016 92
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 93
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac LLC, H2 2016 94
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd, H2 2016 95
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Zenith Capital Corp, H2 2016 96
Assessment by Monotherapy Products, H2 2016 97
Number of Products by Stage and Target, H2 2016 99
Number of Products by Stage and Mechanism of Action, H2 2016 104
Number of Products by Stage and Route of Administration, H2 2016 108
Number of Products by Stage and Molecule Type, H2 2016 110
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2016 443
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2016 444
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2016 445
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2016 446
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H2 2016 447
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2016 448
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2016 449
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..2), H2 2016 450
 

List of Figures

List of Figures
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 19
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Products, H2 2016 28
Assessment by Monotherapy Products, H2 2016 97
Number of Products by Top 10 Targets, H2 2016 98
Number of Products by Stage and Top 10 Targets, H2 2016 98
Number of Products by Top 10 Mechanism of Actions, H2 2016 103
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 103
Number of Products by Top 10 Routes of Administration, H2 2016 107
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 107
Number of Products by Top 10 Molecule Types, H2 2016 109
Number of Products by Stage and Top 10 Molecule Types, H2 2016 109
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 6, 37, 20 and 19 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 463 

Companies Featured

AB Science SA AbbVie Inc Adamis Pharmaceuticals Corp Advaxis Inc Ambrx Inc Amgen Inc Aptevo Therapeutics Inc Armour Therapeutics Inc ArQule Inc Arrowhead Pharmaceuticals Inc Arvinas Inc Asana BioSciences LLC AstraZeneca Plc ATLAB Pharma SAS Aurigene Discovery Technologies Ltd Bavarian Nordic A/S BeiGene Ltd Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp CellCentric Ltd Clovis Oncology Inc Corcept Therapeutics Inc Corvus Pharmaceuticals Inc Curevac AG DexTech Medical AB Eli Lilly and Company Endocyte Inc ESSA Pharma Inc F. Hoffmann-La Roche Ltd Gilead Sciences Inc Glactone Pharma AB GlaxoSmithKline Plc GTx Inc Ionis Pharmaceuticals Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson MedImmune LLC Medivation Inc MEI Pharma Inc Millennium Pharmaceuticals Inc NewLink Genetics Corp Novartis AG Oncogenex Pharmaceuticals Inc Oncolytics Biotech Inc Ono Pharmaceutical Co Ltd Pfizer Inc Progenics Pharmaceuticals Inc Selexel Sotio as Supratek Pharma Inc Taiho Pharmaceutical Co Ltd Takeda Pharmaceutical Company Ltd Tesaro Inc Threshold Pharmaceuticals Inc Tiltan Pharma Ltd Tokai Pharmaceuticals Inc TRACON Pharmaceuticals Inc UbiVac LLC Viralytics Ltd Zenith Capital Corp

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8713IDB has a rating of 95.3 percent
Figure of merit assessment for report 05IB-GMDHC8713IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8713IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [3.73831s]

--